Lancet Subjournal: Caution Advised—Rare Risk Following RSV Vaccination in Older Adults Requires Long-Term Monitoring-VCBeat

DeepEvidence: In-depth Analysis of Medical Evidence to Support Your Decision-making Respiratory syncytial virus (RSV) poses a serious health threat to adults aged 60 and above, potentially causing acute respiratory infections, hospitalization, and even death. Its disease burden is often underestimated due to insufficient medical visits and low awareness. In recent years, three RSV vaccines (GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA) have been successively approved for use in the elderly population. However, their real-world vaccination rates, effectiveness, and safety still require comprehensive validation. To address this, a research team conducted a systematic review and meta-analysis, aggregating real-world data from multiple regions globally to provide evidence-based support for vaccine application strategies. The study, conducted between November 2024 and November 2025, performed monthly searches in databases such as Ovid Medline and Embase, ultimately including 36 studies covering data from 121.8 million people across nine countries, including the United States, the United Kingdom, and Italy. The research period focused on the 2023/24 to 2024/25 RSV seasons. The study utilized Covidence software for deduplication and screening, with two researchers independently completing data extraction and bias risk assessment (based on the JBI tool). Meta-analysis was performed using R software, with a focus on evaluating vaccination rates, effectiveness, and safety, along with subgroup analyses stratified by age, race, comorbidities, and more. Figure: Study Flowchart &nb